argenx (ARGX) Competitors

argenx logo
$649.09 +13.07 (+2.05%)
Closing price 04:00 PM Eastern
Extended Trading
$648.88 -0.21 (-0.03%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARGX vs. SNY, GSK, TAK, BNTX, ONC, TEVA, BGNE, SMMT, ITCI, and VTRS

Should you be buying argenx stock or one of its competitors? The main competitors of argenx include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

argenx vs.

argenx (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.

Sanofi has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$1.27B31.09-$295.05M-$0.88-737.60
Sanofi$44.29B3.13$6.22B$2.4921.91

60.3% of argenx shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, argenx had 3 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for argenx and 16 mentions for Sanofi. Sanofi's average media sentiment score of 1.25 beat argenx's score of 0.95 indicating that Sanofi is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenx
7 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Sanofi
12 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

argenx received 597 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 67.19% of users gave argenx an outperform vote while only 60.98% of users gave Sanofi an outperform vote.

CompanyUnderperformOutperform
argenxOutperform Votes
647
67.19%
Underperform Votes
316
32.81%
SanofiOutperform Votes
50
60.98%
Underperform Votes
32
39.02%

Sanofi has a net margin of 12.77% compared to argenx's net margin of -2.11%. Sanofi's return on equity of 25.58% beat argenx's return on equity.

Company Net Margins Return on Equity Return on Assets
argenx-2.11% -1.45% -1.29%
Sanofi 12.77%25.58%14.70%

argenx presently has a consensus price target of $658.39, suggesting a potential upside of 1.43%. Sanofi has a consensus price target of $60.00, suggesting a potential upside of 9.97%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than argenx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenx
1 Sell rating(s)
2 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.86
Sanofi
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.25

argenx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Summary

Sanofi beats argenx on 11 of the 19 factors compared between the two stocks.

Get argenx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARGX vs. The Competition

MetricargenxBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$39.44B$3.06B$5.68B$9.04B
Dividend YieldN/A1.79%5.32%4.00%
P/E Ratio-737.6047.1990.0319.29
Price / Sales31.09326.101,032.0475.93
Price / CashN/A192.7646.0938.87
Price / Book9.383.975.085.00
Net Income-$295.05M-$40.60M$113.38M$222.75M
7 Day Performance-3.37%-4.58%-1.00%-0.55%
1 Month Performance-1.09%-0.97%4.22%3.03%
1 Year Performance65.29%-9.78%21.48%17.92%

argenx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARGX
argenx
2.5468 of 5 stars
$649.09
+2.1%
$658.39
+1.4%
+58.4%$39.44B$1.27B-737.601,148Positive News
SNY
Sanofi
4.1636 of 5 stars
$53.44
+0.2%
$60.00
+12.3%
+15.9%$135.62B$44.46B21.4686,088Positive News
GSK
GSK
3.3105 of 5 stars
$36.52
+1.3%
$43.25
+18.4%
-13.9%$75.66B$40.10B22.9670,200Earnings Report
Dividend Increase
Analyst Forecast
TAK
Takeda Pharmaceutical
3.1421 of 5 stars
$13.47
-0.5%
N/A-5.7%$42.84B$28.20B33.6649,281
BNTX
BioNTech
3.069 of 5 stars
$115.73
-1.6%
$142.72
+23.3%
+22.9%$27.72B$4.13B-55.076,133
ONC
Beigene
N/A$220.50
-1.3%
N/AN/A$21.55B$2.46B-26.7610,600Analyst Revision
News Coverage
Positive News
TEVA
Teva Pharmaceutical Industries
2.7494 of 5 stars
$16.66
-1.0%
$23.57
+41.5%
+38.4%$18.87B$16.54B-11.4937,851Short Interest ↑
BGNE
BeiGene
1.5119 of 5 stars
N/A$253.69
+∞
N/A$18.03B$3.32B-22.429,000Analyst Forecast
SMMT
Summit Therapeutics
2.4213 of 5 stars
$20.53
+2.1%
$33.57
+63.5%
+324.0%$15.15B$700,000.00-73.35110
ITCI
Intra-Cellular Therapies
3.945 of 5 stars
$127.08
+0.1%
$103.62
-18.5%
+75.3%$13.51B$612.78M-146.09560Short Interest ↑
VTRS
Viatris
3.2185 of 5 stars
$10.72
-0.1%
$13.67
+27.5%
-9.2%$12.78B$15.43B-14.4738,000

Related Companies and Tools


This page (NASDAQ:ARGX) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners